New York, NYNCT06420089Now EnrollingIRB Ready

T Cell Non-Hodgkin Lymphoma Clinical Trial in New York, NY

Access cutting-edge t cell non-hodgkin lymphoma treatment through this phase 1 clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Vittoria Biotherapeutics

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access t cell non-hodgkin lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related t cell non-hodgkin lymphoma treatment provided free

Apply for This New York Location

Check if you qualify for this t cell non-hodgkin lymphoma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This T Cell Non-Hodgkin Lymphoma Study in New York

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.

Sponsor: Vittoria Biotherapeutics

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed relapsed or refractory (r/r) CD5-positive nodal peripheral T-cell lymphoma (such as peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), nodal T-cell lymphomas with T-follicular helper (TFH) phenotype, including follicular T cell lymphoma, angioimmunoblastic lymphoma, or anaplastic large cell lymphoma) or other non-leukemic CD5+ aggressive mature T cell lymphomas (such as enteropathy-associated T cell lymphoma, monomorphic epitheliotropic intestinal T cell lymphoma, transformed mycosis fungoides, primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, primary cutaneous insert gamma delta symbols lymphoma, or subcutaneous panniculitis like T cell lymphoma).
≥50% expression of CD5 on flow cytometry or IHC on malignant cells on the most recent biopsy
Must have received at least one line of prior systemic therapy for their lymphoma; participants with anaplastic large cell lymphoma (ALCL) must have received prior brentuximab unless there was a contraindication to brentuximab.
Evaluable disease defined by at least one lesion that can be measured in least 1 dimension and measures at least 1.5 cm in its longest dimension by CT or PET scan, or bone/bone marrow involvement, or skin involvement.
No circulating CD5+ malignant cells identified by peripheral blood flow cytometry must be present.

Exclusion Criteria

Pregnant or lactating (nursing) women.
HIV infection.
Concurrent use of systemic steroids or immunosuppressant medications.
Any uncontrolled active medical disorder that would preclude participation as outlined.
History of immunodeficiency.
History of prior chimeric antigen receptor therapy (CAR T), autologous or syngeneic HCT \<100 days from transplant at the time of cell infusion or previous allo-HCT.
Active and/or systemic inflammatory or autoimmune diseases.
Signs or symptoms indicative of active CNS involvement.
Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to lymphoma or previous lymphoma treatment.
Clinically apparent arrhythmia, or arrhythmias that are not stable on medical management
Current participation in or prior participation in a study of an investigational agent or using an investigational device within 2 weeks of the first dose of treatment.
Prior monoclonal antibody therapy within 4 weeks prior to study Day 1
Prior use of alemtuzumab
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1
Uncontrolled active infection requiring systemic therapy.
Circulating CD5+ malignant cells identified by peripheral blood flow cytometry present.
Active and/or systemic inflammatory or autoimmune diseases.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT06420089) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

T Cell Non-Hodgkin Lymphoma Treatment Options in New York, NY

If you're searching for t cell non-hodgkin lymphoma treatment options in New York, NY, this clinical trial (NCT06420089) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced t cell non-hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all t cell non-hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in New York, NY

See all lymphoma clinical trials recruiting in New York — not just this study.

Browse Lymphoma Trials in New York →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY